Contraflu, a Singapore-based company, is now raising funds to perform a clinical trial for a product that will target what is now known as drug-resistant influenza. The problem of drug-resistant infections is recognized as the number one threat to humankind that can be mitigated by science (Notation 1). Drug-resistant infections, or super-bugs, can kill 50 million people annually by 2050 leaving cancer behind (Notation 2). Thus, the company is poised to produce the only medicinal product able to regulate the innate host response to influenza. Thanks to a combination of safety, proven efficacy, and low manufacturing cost ($0.3) it is slated to become the number one product for the treatment of flu.